GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Ensysce Biosciences ENSC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.36

+9.98%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ensysce Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Ensysce Biosciences is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ENSC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $5.1m and a net loss of $10.2m. At that date it held total assets of $7.5m and shareholders' equity of $3.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Dec 2017
Employees
7
Website
ensysce.com ↗
Head office
7946 IVANHOE AVENUE, LA JOLLA, CA, 92037
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Bob GowerIndependent Chairman of the Board$25,000
  • Dr. Lynn KirkpatrickPresident, Chief Executive Officer, Director, since 2009$442,392
  • Mr. David HumphreyChief Financial Officer, Treasurer, Secretary$371,267
  • Dr. Jeffrey MillardChief Operating Officer
  • Mr. Geoffrey BirkettChief Commercial Officer$343,634
  • Dr. Linda PestanoChief Development Officer
  • Dr. William SchmidtChief Medical Officer
  • Mr. Andrew BentonIndependent Director$7,500
  • Mr. William ChangIndependent Director$7,500
  • Dr. Adam LevinIndependent Director$10,000
  • Mr. Steve MartinIndependent Director$15,000
  • Ms. Lee RauchIndependent Director$10,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Ensysce Biosciences' TAAP platform reduces opioid misuse and overdose risks effectively.
  • The company's MPAR platform enhances overdose protection for prescription drugs.
  • With 7 employees, Ensysce focuses on innovative biopharmaceutical solutions.

Weaknesses

  • The company has only 7 full-time employees, limiting operational capacity.
  • Ensysce's clinical-stage development requires significant future funding.
  • Limited employee count may hinder rapid market expansion efforts.

Opportunities

  • The US market offers significant growth potential for opioid abuse solutions.
  • Biotechnology sector growth in Health Care drives new opportunities.
  • Ensysce's pipeline could attract partnerships in the Health Care industry.

Threats

  • Regulatory challenges in the US Health Care sector may delay approvals.
  • Competition from larger biotech firms in the opioid solution space.
  • Market volatility in the Health Care industry affects investment stability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.